SCHEMBL13872207

SCHEMBL13872207

C=C1c2cc(-c3cccnc3)ccc2CN1c1ccc2c(ccn2C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 3/20 0.43
▸ CYP11B2 P19099 3/20 0.43
▸ MAP3K5 Q99683 2/20 0.41
▸ FAAH O00519 4/20 0.40
▸ LRRK2 Q5S007 2/20 0.39
▸ HTR1D P28221 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HTR2C P28335 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13872258 0.89 LRRK2 (0.41) FAAHLRRK2DRD2CCNCCDK8
SCHEMBL13113569 0.88 MAP3K5 (0.51) CYP11B1CYP11B2MAP3K5FAAHLRRK2
SCHEMBL13872303 0.83 MAP3K5 (0.43) CYP11B1CYP11B2MAP3K5HTR1DCYP1A2
SCHEMBL3481109 0.80 MAP3K5 (0.51) CYP11B1CYP11B2MAP3K5HTR1DCYP1A2
SCHEMBL13872246 0.79 CYP11B1 (0.43) CYP11B1CYP11B2MAP3K5CYP1A2
SCHEMBL13872269 0.78 PRKCI (0.40) FAAHLRRK2KDM4EMAPT
SCHEMBL13872131 0.78 PRKCI (0.42) FAAHMEN1TP53CYP2D6MAPT
SCHEMBL23187978 0.78 CYP11B2 (0.64) CYP11B1CYP11B2FAAHHTR1DKDM4E
SCHEMBL13872217 0.77 PRKCI (0.39) FAAHLRRK2HTR2C
SCHEMBL13871952 0.77 PRKCI (0.39) FAAHLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009042907-A1 ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-04-02 — — WO disclosed
Send feedback